ArticleJAMA2026

Cost-Effectiveness of ApoB, Non-HDL-C, and LDL-C Goals for Primary Prevention Lipid-Lowering Therapy.

Samuel Luebbe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.